Distinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits
dc.contributor.author | Sikaris, Ken Andrew | |
dc.contributor.author | Streichert, Thomas | |
dc.contributor.author | Macri, Joseph | |
dc.contributor.buuauthor | İlçöl, Yeşim Özarda | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbı Biyokimya Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAL-8873-2021 | tr_TR |
dc.contributor.scopusid | 35741320500 | tr_TR |
dc.date.accessioned | 2022-12-21T12:13:49Z | |
dc.date.available | 2022-12-21T12:13:49Z | |
dc.date.issued | 2018-05-18 | |
dc.description.abstract | Reference Intervals (RIs) and clinical decision limits (CDLs) are a vital part of the information supplied by laboratories to support the interpretation of numerical clinical pathology results. RIs describe the typical distribution of results seen in a healthy reference population while CDLs are associated with a significantly higher risk of adverse clinical outcomes or are diagnostic for the presence of a specific disease. However, as the two concepts are sometimes confused, there is a need to clarify the differences between these terms and to ensure they are easily distinguished, especially because CDLs have a clinical association with specific diseases and risks, thereby implying that effective clinical interventions are available. It is important to note that, because population-based RIs are derived from the range of values expected in a typical community population, laboratory results that fall outside a RI do not necessarily indicate a disease but rather that additional medical follow-up and/or treatment may be warranted. In contrast, CDLs are associated with a risk of specific adverse outcomes, and are commonly used to interpret laboratory test results, including lipid parameters, glucose, hemoglobin A1c (HbA1c), and tumor markers, to determine risk of disease, to diagnose or to treat. In recent years, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Reference Intervals and Decision Limits (C-RIDL) has focused primarily on RIs and has performed multicenter studies to obtain common RIs. However, the broader responsibility of the Committee, from its name, includes decision limits. C-RIDL now aims to emphasize the importance of the correct use of both RIs and CDLs and to encourage laboratories to specify the appropriate information to clinicians as needed. This review discusses RIs and CDLs in detail, describes the similarities and the differences between these two important tools in laboratory medicine, and clearly explains the processes used to define them. C-RIDL encourages the involvement of laboratory professionals in the establishment of both RIs and CDLs. | en_US |
dc.identifier.citation | Özarda, Y. vd. (2018). ''Distinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits''. Critical Reviews in Clinical Laboratory Sciences, 55(6), 420-431. | en_US |
dc.identifier.endpage | 431 | tr_TR |
dc.identifier.issn | 1040-8363 | |
dc.identifier.issn | 1549-781X | |
dc.identifier.issue | 6 | tr_TR |
dc.identifier.pubmed | 30047297 | tr_TR |
dc.identifier.scopus | 2-s2.0-85051077162 | tr_TR |
dc.identifier.startpage | 420 | tr_TR |
dc.identifier.uri | https://doi.org/10.1080/10408363.2018.1482256 | |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/10408363.2018.1482256 | |
dc.identifier.uri | http://hdl.handle.net/11452/30010 | |
dc.identifier.volume | 55 | tr_TR |
dc.identifier.wos | 000440701500003 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor and Francis | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Critical Reviews in Clinical Laboratory Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Reference intervals | en_US |
dc.subject | Clinical decision limits | en_US |
dc.subject | C-RIDL | en_US |
dc.subject | Clinical laboratories | en_US |
dc.subject | Prostate-specific antigen | en_US |
dc.subject | European atherosclerosis society | en_US |
dc.subject | Prediatric peference intervals | en_US |
dc.subject | Approved recommendation1987 | en_US |
dc.subject | Joint consensus statement | en_US |
dc.subject | High-density-lipoprotein | en_US |
dc.subject | Reference values | en_US |
dc.subject | 99th percentile | en_US |
dc.subject | Analytical performance | en_US |
dc.subject | Global multicenter | en_US |
dc.subject | Medical laboratory technology | en_US |
dc.subject.emtree | Glucose | en_US |
dc.subject.emtree | Hemoglobin A1c | en_US |
dc.subject.emtree | Lipid | en_US |
dc.subject.emtree | Clinical decision limit | en_US |
dc.subject.emtree | Clinical decision making | en_US |
dc.subject.emtree | Health care organization | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Laboratory test | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Reference value | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Laboratory | en_US |
dc.subject.emtree | Laboratory technique | en_US |
dc.subject.emtree | Organization and management | en_US |
dc.subject.emtree | Standards | en_US |
dc.subject.mesh | Clinical laboratory techniques | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Laboratories | en_US |
dc.subject.mesh | Reference values | en_US |
dc.subject.scopus | Clinical Chemistry; Thyrotropin; Chemical Species | en_US |
dc.subject.wos | Medical laboratory technology | en_US |
dc.title | Distinguishing reference intervals and clinical decision limits – A review by the IFCC committee on reference intervals and decision limits | en_US |
dc.type | Review | |
dc.wos.quartile | Q1 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: